Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
N/A
1(25.0%)
4Total
Phase 4(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01939951Phase 4Unknown

Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.

Role: lead

NCT01939964Not ApplicableUnknown

Study to Determine Effectiveness of Activation Mist on Facial Skin Wrinkles

Role: lead

NCT01635088Phase 4Completed

Onset and Duration of Mometasone by Oscillometry and Spirometry

Role: lead

NCT01781507Phase 4Completed

Study of Bronchodilation Effects of Cetirizine

Role: lead

All 4 trials loaded